ERNA
Price
$0.18
Change
-$0.01 (-5.26%)
Updated
Apr 3 closing price
Capitalization
9.61M
SMMT
Price
$18.91
Change
-$1.55 (-7.58%)
Updated
Apr 3 closing price
Capitalization
13.94B
34 days until earnings call
Ad is loading...

ERNA vs SMMT

Header iconERNA vs SMMT Comparison
Open Charts ERNA vs SMMTBanner chart's image
Ernexa Therapeutics
Price$0.18
Change-$0.01 (-5.26%)
Volume$321.58K
Capitalization9.61M
Summit Therapeutics
Price$18.91
Change-$1.55 (-7.58%)
Volume$3.46M
Capitalization13.94B
ERNA vs SMMT Comparison Chart
Loading...
ERNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SMMT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ERNA vs. SMMT commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ERNA is a Hold and SMMT is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (ERNA: $0.18 vs. SMMT: $18.91)
Brand notoriety: ERNA and SMMT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ERNA: 89% vs. SMMT: 144%
Market capitalization -- ERNA: $9.61M vs. SMMT: $13.94B
ERNA [@Biotechnology] is valued at $9.61M. SMMT’s [@Biotechnology] market capitalization is $13.94B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.17B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ERNA’s FA Score shows that 0 FA rating(s) are green whileSMMT’s FA Score has 2 green FA rating(s).

  • ERNA’s FA Score: 0 green, 5 red.
  • SMMT’s FA Score: 2 green, 3 red.
According to our system of comparison, SMMT is a better buy in the long-term than ERNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ERNA’s TA Score shows that 4 TA indicator(s) are bullish while SMMT’s TA Score has 2 bullish TA indicator(s).

  • ERNA’s TA Score: 4 bullish, 4 bearish.
  • SMMT’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, ERNA is a better buy in the short-term than SMMT.

Price Growth

ERNA (@Biotechnology) experienced а -20.02% price change this week, while SMMT (@Biotechnology) price change was -8.20% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.89%. For the same industry, the average monthly price growth was -11.08%, and the average quarterly price growth was -14.87%.

Reported Earning Dates

ERNA is expected to report earnings on May 11, 2023.

SMMT is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (-8.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SMMT($13.9B) has a higher market cap than ERNA($9.61M). SMMT YTD gains are higher at: 5.968 vs. ERNA (-38.435). ERNA has higher annual earnings (EBITDA): -36.12M vs. SMMT (-212.51M). SMMT has more cash in the bank: 412M vs. ERNA (1.73M). ERNA has less debt than SMMT: ERNA (684K) vs SMMT (7.22M). ERNA has higher revenues than SMMT: ERNA (582K) vs SMMT (0).
ERNASMMTERNA / SMMT
Capitalization9.61M13.9B0%
EBITDA-36.12M-212.51M17%
Gain YTD-38.4355.968-644%
P/E RatioN/A26.36-
Revenue582K0-
Total Cash1.73M412M0%
Total Debt684K7.22M9%
FUNDAMENTALS RATINGS
ERNA vs SMMT: Fundamental Ratings
ERNA
SMMT
OUTLOOK RATING
1..100
5076
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
95
Overvalued
PROFIT vs RISK RATING
1..100
10031
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
9635
P/E GROWTH RATING
1..100
1006
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ERNA's Valuation (59) in the Medical Specialties industry is somewhat better than the same rating for SMMT (95) in the Biotechnology industry. This means that ERNA’s stock grew somewhat faster than SMMT’s over the last 12 months.

SMMT's Profit vs Risk Rating (31) in the Biotechnology industry is significantly better than the same rating for ERNA (100) in the Medical Specialties industry. This means that SMMT’s stock grew significantly faster than ERNA’s over the last 12 months.

SMMT's SMR Rating (98) in the Biotechnology industry is in the same range as ERNA (100) in the Medical Specialties industry. This means that SMMT’s stock grew similarly to ERNA’s over the last 12 months.

SMMT's Price Growth Rating (35) in the Biotechnology industry is somewhat better than the same rating for ERNA (96) in the Medical Specialties industry. This means that SMMT’s stock grew somewhat faster than ERNA’s over the last 12 months.

SMMT's P/E Growth Rating (6) in the Biotechnology industry is significantly better than the same rating for ERNA (100) in the Medical Specialties industry. This means that SMMT’s stock grew significantly faster than ERNA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ERNASMMT
RSI
ODDS (%)
Bullish Trend 1 day ago
71%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
83%
Bullish Trend 1 day ago
87%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 1 day ago
84%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
84%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 12 days ago
86%
Declines
ODDS (%)
Bearish Trend 8 days ago
90%
Bearish Trend 4 days ago
81%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
85%
N/A
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 3 days ago
87%
View a ticker or compare two or three
Ad is loading...
ERNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SMMT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VIV9.300.31
+3.45%
Telefonica Brasil SA
USM68.71-1.00
-1.43%
United States Cellular Corp
CATX1.96-0.09
-4.39%
Perspective Therapeutics
IDAI1.78-0.10
-5.32%
T Stamp Inc
SACH1.05-0.06
-5.41%
Sachem Capital Corp

ERNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ERNA has been loosely correlated with CGEN. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ERNA jumps, then CGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ERNA
1D Price
Change %
ERNA100%
-5.24%
CGEN - ERNA
39%
Loosely correlated
-3.42%
MDGL - ERNA
36%
Loosely correlated
-2.24%
IBIO - ERNA
32%
Poorly correlated
-7.77%
SMMT - ERNA
31%
Poorly correlated
-7.58%
CYTK - ERNA
29%
Poorly correlated
+0.67%
More